Delamanid is a new anti-tuberculosis drug: use, limitations, and prospects
-
Published:2021-03-10
Issue:2
Volume:99
Page:58-66
-
ISSN:2542-1506
-
Container-title:Tuberculosis and Lung Diseases
-
language:
-
Short-container-title:Tuberk. bolezni lëgk.
Author:
Zimina V. N.1, Viktorova I. B.2ORCID
Affiliation:
1. Peoples’ Friendship University of Russia; National Medical Research Center of Phthisiopulmonology and Infectious Diseases 2. Novokuznetsk State Institute for Doctors' Professional Development – Branch of Russian Medical Academy of Continuing Professional Education
Abstract
The review analyses 61 publications on the use of delamanid, a new drug for the treatment of drug resistant tuberculosis. It presents information about pharmacokinetic parameters, efficacy and safety, as well as the place of delamanid in the combination therapy of multiple drug resistant tuberculosis. It tells about specific parameters of delamanid use in children and HIV patients.
Reference60 articles.
1. Gayda А.I., Sveshnikova O.M., Verkhovaya V.N., Makhmaeva S.V., Nikishova E.I., Maryandyshev А.O. Treatment of tuberculosis patients with extensive drug resistance using new anti-tuberculosis drugs in the civilian community of Arkhangelsk Region. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 7, pp. 5-10. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-7-5-10. 2. Lorsanov S.M., Khaydarkhanova Z.B., Khunkarsultanov S.B. The experience of using delamanid in the Chechen Republic. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 12, pp. 62-63. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-12-62-63. 3. Maryandyshev А.O., Lorsanov S.M., Khaydarkhanova Z.B., Khunkarsultanov S.B., Perkhin D.V., Sveshnikova O.M., Gayda А.I., Privolnev V.V. Treatment outcomes of regimens containing delamanid within therapy of multiple and extensive drug resistant tuberculosis in the Russian Federation. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 11, pp. 67-68. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-11-67-68. 4. A 6-month safety, efficacy and pharmacokinetic trial of delamanid in pediatric patients with multidrug resistant tuberculosis (Protocol 242-12-233), 2013. [NCT01859923] https://clinicaltrials.gov/ct2/show/NCT01859923. 5. Akkerman O., Aleksa A., Alffenaar J. W., Al-Marzouqi N. H., Arias-Guillén M., Belilovski E., Bernal E., Boeree M. J., Borisov S. E., Bruchfeld J., Cadiñanos Loidi J., Cai Q., Caminero J. A., Cebrian Gallardo J. J., Centis R., Codecasa L. R., D'Ambrosio L., Dalcolmo M., Danila E., Dara M., Davidavičienė E., Davies Forsman L., De Los Rios Jefe J., Denholm J., Duarte R., Elamin S. E., Ferrarese M., Filippov A., Ganatra S., Garcia A., García-García J. M., Gayoso R., Giraldo Montoya A. M., Gomez Rosso R. G., Gualano G., Hoefsloot W., Ilievska-Poposka B., Jonsson J., Khimova E., Kuksa L., Kunst H., Laniado-Laborín R., Li Y., Magis-Escurra C., Manfrin V., Manga S., Marchese V., Martínez Robles E., Maryandyshev A., Matteelli A., Migliori G. B., Mullerpattan J. B., Munoz-Torrico M., Mustafa Hamdan H., Nieto Marcos M., Noordin N. M., Palmero D. J., Palmieri F., Payen M. C., Piubello A., Pontali E., Pontarelli A., Quirós S., Rendon A., Skrahina A., Šmite A., Solovic I., Sotgiu G., Souleymane M. B., Spanevello A., Stošić M., Tadolini M., Tiberi S., Udwadia Z. F., van den Boom M., Vescovo M., Viggiani P., Visca D., Zhurkin D., Zignol M., members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study // Int. J. Infect. Dis. ‒ 2019. ‒ Vol. 83. ‒ Р. 72-76. doi: 10.1016/j.ijid.2019.03.036. Epub. 2019 Apr 3. PMID: 30953827.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|